At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
XCUR Exicure, Inc.
Trading 06-15 14:47:34 EDT
3.01
+0.23
+8.09%
High3.01Low2.71Vol31.87K
Open2.75D1 Closing2.78Amplitude10.61%
Mkt Cap19.15MTradable Cap7.00MTotal Shares6.37M
T/O92.89KT/O Rate1.37%Tradable Shares2.33M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Exicure gets Nasdaq notice for falling below $2.5 million stockholders’ equity requirement
Reuters  ·  06-11
Exicure gets Nasdaq notice for falling below $2.5 million stockholders’ equity requirement
Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity Requirement
THOMSON REUTERS  ·  06-11
Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity Requirement
Exicure receives noncompliance notification from Nasdaq
TIPRANKS  ·  06-02
Exicure receives noncompliance notification from Nasdaq
Exicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-Q
THOMSON REUTERS  ·  06-02
Exicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-Q
Exicure - Files Q1 2026 10-Q on May 29, 2026; Believes Nasdaq Compliance Regained
THOMSON REUTERS  ·  06-02
Exicure - Files Q1 2026 10-Q on May 29, 2026; Believes Nasdaq Compliance Regained
Exicure Q1 EPS $(0.29) Down From $0.49 YoY
Benzinga  ·  05-30
Exicure Q1 EPS $(0.29) Down From $0.49 YoY
Exicure Q1 FY26 net loss widens to $1.83 million; R&D expense drops 61% to $312,000
Reuters  ·  05-30
Exicure Q1 FY26 net loss widens to $1.83 million; R&D expense drops 61% to $312,000
Exicure delays filing quarterly report, seeks five-day extension under SEC rules
Reuters  ·  05-16
Exicure delays filing quarterly report, seeks five-day extension under SEC rules
BRIEF-Exicure announces co-development agreement with Adbiotech for Burixafor (Gpc-100)
Reuters  ·  04-23
BRIEF-Exicure announces co-development agreement with Adbiotech for Burixafor (Gpc-100)
Exicure partners with Adbiotech to co-develop Burixafor combination therapies
Reuters  ·  04-23
Exicure partners with Adbiotech to co-develop Burixafor combination therapies
Exicure Announces Co-Development Agreement With Adbiotech for Burixafor (Gpc-100)
THOMSON REUTERS  ·  04-23
Exicure Announces Co-Development Agreement With Adbiotech for Burixafor (Gpc-100)
Exicure names Young Seung Ko chief operating officer
Reuters  ·  04-11
Exicure names Young Seung Ko chief operating officer
Exicure Inc - Announces Settlement of Stockholder Derivative Action per March 18, 2026 Stipulation
THOMSON REUTERS  ·  04-03
Exicure Inc - Announces Settlement of Stockholder Derivative Action per March 18, 2026 Stipulation
Exicure reaches settlement in stockholder derivative litigation, adopts governance reforms
Reuters  ·  04-03
Exicure reaches settlement in stockholder derivative litigation, adopts governance reforms
Exicure board changes; Sangjin Yeo resigns from board and audit committee effective March 27, 2026
Reuters  ·  03-28
Exicure board changes; Sangjin Yeo resigns from board and audit committee effective March 27, 2026
Exicure Q4 EPS $(0.22) Up From $(3.39) YoY.
Benzinga  ·  03-26
Exicure Q4 EPS $(0.22) Up From $(3.39) YoY.
Press Release: Exicure, Inc. Reports Full Year 2025 Financial Results
Dow Jones  ·  03-26
Press Release: Exicure, Inc. Reports Full Year 2025 Financial Results
Top News Today: Stocks Slide, Treasury Yields Rise Amid Oil Shock
Dow Jones  ·  03-21
Top News Today: Stocks Slide, Treasury Yields Rise Amid Oil Shock
Top News Today/Canada: Retail Sales Rose 1.1% in January
Dow Jones  ·  03-21
Top News Today/Canada: Retail Sales Rose 1.1% in January
Exicure Inc - Appoints Gyuyeob Lee as Interim CFO - SEC Filing
THOMSON REUTERS  ·  02-18
Exicure Inc - Appoints Gyuyeob Lee as Interim CFO - SEC Filing

Introduction

Company Name.
Exicure, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Exicure, Inc. does not have significant operations. previously, the company focused on developing of nucleic acid therapies targeting ribonucleic acid against validated targets. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.
Issue price:
--